

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 December 14; 23(46): 8109-8262



W

J

G

**REVIEW**

- 8109** Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer  
*Sipos F, Székely H, Kis ID, Tulassay Z, Múzes G*

**MINIREVIEWS**

- 8120** Retreatment of patients with treatment failure of directacting antivirals: Focus on hepatitis C virus genotype 1b  
*Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M*

**ORIGINAL ARTICLE****Basic Study**

- 8128** Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice  
*Wang X, Ye T, Chen WJ, Lv Y, Hao Z, Chen J, Zhao JY, Wang HP, Cai YK*
- 8140** miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1  
*Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RY, Zhao ZH, Pan Q, Fan JG*
- 8152** *In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis  
*Zhang GZ, Sun HC, Zheng LB, Guo JB, Zhang XL*
- 8169** Pharmacokinetics and pharmacodynamics of Shengjiang decoction in rats with acute pancreatitis for protecting against multiple organ injury  
*Zhu L, Li JY, Zhang YM, Kang HX, Chen H, Su H, Li J, Tang WF*

**Retrospective Cohort Study**

- 8182** Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease  
*Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D'Haens G, Löwenberg M, Weersma RK, Festen EAM; PARELSNOER Institute and the Dutch Initiative on Crohn and Coliti*

**Retrospective Study**

- 8193** Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?  
*Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP*

- 8200** Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen  
*Futawatari N, Fukuyama T, Yamamura R, Shida A, Takahashi Y, Nishi Y, Ichiki Y, Kobayashi N, Yamazaki H, Watanabe M*

- 8207** Diagnostic classification of endosonography for differentiating colorectal ulcerative diseases: A new statistical method  
*Qiu EQ, Guo W, Cheng TM, Yao YL, Zhu W, Liu SD, Zhi FC*

**Clinical Trial Study**

- 8217** Characteristics of fecal microbial communities in patients with non-anastomotic biliary strictures after liver transplantation  
*Zhang J, Ren FG, Liu P, Zhang HK, Zhu HY, Feng Z, Zhang XF, Wang B, Liu XM, Zhang XG, Wu RQ, Lv Y*

**Observational Study**

- 8227** Balloon dilatation for treatment of hepatic venous outflow obstruction following pediatric liver transplantation  
*Zhang ZY, Jin L, Chen G, Su TH, Zhu ZJ, Sun LY, Wang ZC, Xiao GW*

**Prospective Study**

- 8235** Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China  
*Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B*

**CASE REPORT**

- 8248** Are liver nested stromal epithelial tumors always low aggressive?  
*Meletani T, Cantini L, Lanese A, Nicolini D, Cimadamore A, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R*
- 8256** Combined thoracoscopic and endoscopic surgery for a large esophageal schwannoma  
*Onodera Y, Nakano T, Takeyama D, Maruyama S, Taniyama Y, Sakurai T, Heishi T, Sato C, Kumagai T, Kamei T*

**LETTER TO THE EDITOR**

- 8261** Extended pelvic side wall excision for locally advanced rectal cancers  
*Shaikh IA, Jenkins JT*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Antonio Macri, MD, Associate Professor, Department of Human Pathology, University of Messina, Messina 98125, Italy

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

I-IX Editorial Board

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Yu-Jie Ma*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*  
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

EDITORS-IN-CHIEF  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS  
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE  
Jin-Lei Wang, Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.fjpublishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLISHER  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.fjpublishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLICATION DATE  
December 14, 2017

COPYRIGHT  
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS  
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.fjpublishing.com>

## Prospective Study

**Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China**

Jin-Min Chen, Tao Liu, Shan Gao, Xu-Dong Tong, Fei-Hong Deng, Biao Nie

Jin-Min Chen, Shan Gao, Xu-Dong Tong, Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China

Tao Liu, Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510665, Guangdong Province, China

Fei-Hong Deng, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China

Biao Nie, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, Guangdong Province, China

ORCID number: Jin-Min Chen (0000-0002-1842-064X); Tao Liu (0000-0003-3336-7207); Shan Gao (0000-0002-8232-4134); Xu-Dong Tong (0000-0002-3136-1242); Fei-Hong Deng (0000-0001-7711-4880); Biao Nie (0000-0002-5702-3540).

**Author contributions:** Chen JM and Nie B designed the study and wrote the manuscript; Deng FH collected fecal and blood samples and completed patient case report; Liu T and Nie B performed all endoscopies and completed the endoscopic scoring sheet; Tong XD quantified fecal calprotectin; Gao S performed data analysis; all authors read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China to Biao Nie, No. 81471080.

**Institutional review board statement:** The study was reviewed and approved by the institutional review board of Department of Gastroenterology in Nanfang Hospital (Guangzhou, China) and the Medical Ethnic Committee of Nanfang Hospital (NFEC-2014-065).

**Clinical trial registration statement:** The clinical trial was registered in Chinese Clinical Trial Registry (registration ID:

ChiCTR-DDT-14005066). Details can be found at <http://www.chictr.org.cn/showproj.aspx?proj=4509>.

**Informed consent statement:** All study participants provided written informed consent prior to study enrollment.

**Conflict-of-interest statement:** The authors of this manuscript have no conflicts of interest to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at email: [niebiao2@163.com](mailto:niebiao2@163.com). Participants gave informed consent for data sharing.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Biao Nie, MD, PhD, Professor, Associate Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, No. 614, West Huangpu Avenue, Guangzhou 510630, Guangdong Province, China. [niebiao2@163.com](mailto:niebiao2@163.com)  
Telephone: +86-15101503392  
Fax: +86-20-38688025

**Received:** July 31, 2017

**Peer-review started:** August 1, 2017

**First decision:** September 6, 2017

**Revised:** September 28, 2017

**Accepted:** November 2, 2017

**Article in press:** November 2, 2017

**Published online:** December 14, 2017

## Abstract

### AIM

To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).

### METHODS

Fecal calprotectin (FC), clinical activity index (CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome (IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn's disease (CICD) with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and ulcerative colitis (UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test,  $\chi^2$  test, Spearman's correlation, and multiple linear regression analysis.

### RESULTS

The median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 0-49.7)  $\mu\text{g/g}$ , respectively ( $P < 0.001$ ). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC ( $r = 0.802$ ), followed by CDAI ( $r = 0.734$ ), CRP ( $r = 0.658$ ), and ESR ( $r = 0.557$ ). The Mayo score also correlated significantly with FC ( $r = 0.837$ ), CAI ( $r = 0.776$ ), ESR ( $r = 0.644$ ), and CRP ( $r = 0.634$ ). For FC, a cut-off value of 250  $\mu\text{g/g}$  indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity (CFA) calculated as  $0.8 \times \text{FC} + 4.6 \times \text{CDAI}$  showed higher area under the curve (AUC) of 0.962 for CICD and CFA calculated as  $0.2 \times \text{FC} + 50 \times \text{CAI}$  showed higher AUC (0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients.

### CONCLUSION

FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation.

**Key words:** Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Fecal calprotectin; Disease activity

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This was a prospective study conducted in China to assess the efficacy of noninvasive markers, including fecal calprotectin, clinical activity index (CAI), CRP, ESR, and procalcitonin (PCT) for monitoring disease activity in colonic or ileo-colonic Crohn's disease (CICD), CD-related surgery patients, and UC patients and further to optimize the accuracy of those noninvasive biomarkers in detecting active residual mucosal inflammation in IBD patients in clinical remission.

Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. *World J Gastroenterol* 2017; 23(46): 8235-8247 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i46/8235.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i46.8235>

## INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic, destructive inflammatory disease of the gastrointestinal tract with unknown etiology<sup>[1]</sup>. Generally, it occurs most commonly at a young age and most patients need life-long medicine treatment, thus causing work disabilities and imposing heavy social and economic burdens<sup>[2]</sup>. IBD is no more than a "Western disease"; according to a multicenter study, IBD in Asia might be as severe as or worse than in the West, and China has the highest incidence of IBD in Asia<sup>[3]</sup>. Two recent prospective population-based studies also demonstrated that IBD has a high incidence and wide geographical coverage in China<sup>[4,5]</sup>.

Because IBD has a chronic relapsing-remitting course, patients and clinicians need a monitoring technique to detect an imminent flare for timely tailoring therapy regimen. To date, most clinicians monitor IBD activity and guide therapeutic decisions based on clinical activity indexes<sup>[6]</sup>. However, emerging data showed that IBD patients with a clinically quiescent disease may still have residual mucosal inflammation and remission of symptoms may not be an available predictor of long-term favorable outcome in IBD patients<sup>[7,8]</sup>. Mucosal healing (MH) has been proven to be a strong predictor of disease-related outcomes and has become a new therapeutic goal in IBD<sup>[9-11]</sup>. An endoscopic procedure for IBD can determine the disease location and mucosal lesions precisely and is considered the gold standard for assessing disease activity. However, endoscopy is invasive, uncomfortable, expensive, and not well tolerated by patients; therefore, regular monitoring of disease activity using endoscopy is not feasible<sup>[12]</sup>. Furthermore, some patients are terrified by painful

endoscopy experiences and they are reluctant to visit clinicians until the disease manifests as rectal bleeding or obstruction, which affects the prognosis. A simple, acceptable, and specific evaluation is needed to play an adjunctive role in the assessment of disease activity, enabling the most cost-effective use of medical resources<sup>[13,14]</sup>.

Clinical assessment indexes correlate poorly with endoscopic activity and remission of symptoms may not indicate remission of IBD<sup>[11,15]</sup>. Also, for patients with clinically overt relapse, their recent history and symptoms will give sufficient reasons for further endoscopic exploration or intensification of treatment, and there is no need to wait for the results of inflammatory biomarkers. Therefore, finding an evaluation that can detect increased endoscopic disease activity earlier before any clinical symptoms have occurred is an unmet clinical need.

The aim of this study, therefore, was to assess the efficacy of noninvasive evaluations, including fecal calprotectin (FC), clinical activity index (CAI or CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) for monitoring disease activity in colonic or ileo-colonic Crohn's disease (CICD), CD-related surgery patients, and UC patients and further to optimize the accuracy of those noninvasive evaluations in detecting active residual mucosal inflammation in IBD patients in clinical remission.

## MATERIALS AND METHODS

### Participants

This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2014-065). In this prospective study, we consecutively recruited 136 adult outpatients and inpatients with previously confirmed diagnoses of IBD referred for colonoscopy at the Department of Gastroenterology of Nanfang Hospital. The diagnosis of IBD was based on clinical, ileocolonoscopy, histopathological, and radiological findings. A second cohort of 25 IBS patients, defined according to the Rome III criteria, served as controls. Of the 136 IBD patients, six had undergone colonoscopy twice to evaluate therapy efficiency, and the interval between the two endoscopies was longer than 2 mo. First, 35 IBD patients were excluded because we could not timely collect a fecal sample before bowel preparation ( $n = 10$ ), a full colonoscopy was not performed due to a stricture or without a properly prepared colon compatible with adequate endoscopic assessment ( $n = 7$ ), the age was  $< 18$  years ( $n = 4$ ), blood samples were missed ( $n = 5$ ), patients used non-steroidal anti-inflammatory drugs (NSAIDs) ( $n = 3$ ), patients had poor compliance with fecal sampling ( $n = 4$ ), or patients had concomitant colorectal cancer ( $n = 2$ ). Outpatients were provided with a fecal collection

tube when they attended the endoscopy center to make an appointment with the physician and were asked to return a fecal sample before the endoscopic examination. In inpatients, the fecal collection set was prepared by a trained nurse and then sent to the laboratory.

For IBD patients, the day before the endoscopy, blood samples were taken to measure CRP, ESR, and PCT in the IBD Unit at Nanfang Hospital. At the same time, the patients were asked to complete a case report to record their demographic data, symptoms, and current medication usage.

### Inclusion criteria

A firm diagnosis of IBD must have been made or confirmed based on clinical, ileocolonoscopy, histopathological, and radiological findings at our institution. Other inclusion criteria were complete colonoscopy (ileum or neo-terminal ileum was included), age between 18 and 85 years, and fecal samples delivered from 1 to 3 d before bowel preparation.

### Exclusion criteria

The exclusion criteria included terminal ileum or neo-terminal ileum not reached; history of extensive bowel resection unrelated to IBD; indeterminate colitis (IC); pregnancy; age  $< 18$  years or  $> 85$  years; other deceptive reasons for elevated CRP/EST/PCT, such as infection (within one month), malignancy (current), rheumaimmune systemic diseases not related to IBD, trauma or surgery (within one month); and use of NSAIDs within three months before colonoscopic examination.

### Endoscopic disease activity

The endoscopic activities of IBD patients were graded according to validated endoscopic score tools. Simple endoscopic score for Crohn's disease" (SES-CD) was used for the CICD patients<sup>[16]</sup>. For the SES-CD, the four endoscopic parameters selected were ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and stenosis. Each variable was scored from 0 to 3 in each segment (the ileum, the right, transverse, and left colon, and the rectum). The SES-CD activity levels were graded as follows: inactive (remission), 0-3; mild activity, 4-10; moderate activity, 11-19; and severe activity,  $\geq 20$ , according to Schoepfer *et al.*<sup>[17]</sup>. The Rutgeerts score is a well-established endoscopic scoring system for assessing the neo-terminal ileum for patients having prior CD-related surgery<sup>[18]</sup>: i0, no lesion; i1,  $< 5$  aphthous lesions; i2,  $> 5$  aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileo-colonic anastomosis; i3, diffuse aphthous ileitis with diffusely inflamed mucosa; and i4, diffuse inflammation with larger ulcers, nodules, and/or narrowing (i0-i1: endoscopic remission;  $\geq i2$ : endoscopic recurrence).

**Table 1 Clinical and demographic characteristics of included patients *n* (%)**

	CD	UC	IBS
Number of patients, <i>n</i>	92	44	25
Male	54 (58.7)	26 (59.1)	11 (44)
Median age at test (range)	29.5 (18-62)	38 (19-70)	35 (21-52)
Age at diagnosis (yr)			NA
A1 (< 16)	7 (7.6)	2 (4.5)	
A2 (17-40)	69 (75.0)	27 (61.4)	
A3 (> 40)	16 (17.4)	15 (34.1)	
Disease location			NA
Ileum (L1)	22 (23.9)	NA	
Colonic (L2)	10 (10.9)	NA	
Ileum-Colonic (L3)	60 (65.2)	NA	
Upper GI (L4)	9 (9.8)	NA	
Rectum (E1)	NA	15 (34.1)	
Distal colitis (E2)	NA	14 (31.8)	
Extensive colitis (E3)	NA	15 (34.1)	
Concomitant medications <sup>1</sup>			NA
No medication	9 (9.8)	3 (6.8)	
5-ASA	28 (30.4)	37 (84.1)	
Corticosteroids	22 (23.9)	9 (20.5)	
Immunosuppressants	39 (42.4)	1 (2.31)	
Anti-TNF therapy	36 (39.1)	4 (9.1)	
Previous IBD-related surgery: no/yes	69/23	NA	NA

<sup>1</sup>Because therapy regimens overlapped, the total is not 100%. GI: Gastrointestinal; ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; NA: Not applicable; IBS: Irritable bowel syndrome; CD: Crohn's disease; UC: Ulcerative colitis.

The disease severity of UC was evaluated according to the Mayo score scale (0-2: remission; 3-5: mild; 6-10: moderate; 11-12: severe)<sup>[19]</sup>.

All endoscopies were performed by two experienced gastroenterologists with at least 5 years of experience in performing colonoscopies. The endoscopists completed an endoscopic scoring sheet immediately after the colonoscopic examination. To minimize the subjective nature of the scoring tools, we recorded a video of the endoscopy procedure. The two endoscopists analyzed the videos together and disagreements were resolved by discussion to realize consistent scoring. To avoid bias, the endoscopists performing the endoscopies were unaware of the FC, clinical activity index, CRP, ESR, and PCT results.

## FC

Upon arrival of stool samples at the laboratory, we sampled from six sites in each stool sample and mixed the sample with a stirrer. One volume of feces was diluted with 49 volumes of extraction buffer. After homogenizing by vigorous shaking for 30 min, the sample was centrifuged at 3000 *g* for 10 min and the supernatant was stored at -20 °C until analysis. The Bühlmann Calprotectin ELISA kit (Bühlmann, Schönenbuch, Switzerland) was designed for the quantitative determination of FC in stool samples. The assay was performed according to the manufacturer's instructions. Briefly, after a short extraction procedure, we diluted the stool extracts 1:150 with incubation buffer. Then, the calprotectin antigen was measured

by sandwich ELISA; the ELISA plates were read at 450 nm using a Spectra mini-reader. All results were normalized to stool wet weight (in grams), and FC concentrations are expressed in µg/g. The researcher carrying out the analyses was blinded to the identity of the patients and their clinical or endoscopic findings.

## Clinical activity and serological biomarkers

For CD patients, clinical activity was assessed based on the "Crohn's disease activity index" (CDAI; ≤ 150: clinical remission; 150-220: mild clinical activity; 220-450: moderate clinical activity; ≥ 450: severe clinical activity)<sup>[20]</sup>. For UC patients, clinical activity was assessed by the "clinical colitis activity index" (CAI; ≤ 4: clinical remission; 5-10: mild clinical activity; 11-17: moderate clinical activity; ≥ 18: severe clinical activity) according to Rachmilewitz<sup>[21]</sup>. Serological biomarkers included CRP (upper limit of normal, 5 mg/L), ESR (upper limit of normal, 10 mm/h), and PCT (lower limit of range, 0.02 ng/mL; upper limit of normal, 0.05 ng/mL).


## Statistical analysis

Data were recorded in an Excel sheet (Microsoft Excel 2007) and analyzed using SPSS software (ver. 15.0 for Windows; SPSS, China). The normality of the distribution of data was tested using the Kolmogorov-Smirnov test. The Mann-Whitney test was used to assess differences between groups. Non-parametric data were presented as medians and interquartile ranges (IQR) or ranges. Non-parametric tests were used when data were not normally distributed. The  $\chi^2$  test was used to assess associations of categorical data in two independent groups. A Bonferroni adjustment was carried out in multiple testing of noninvasive parameters according to endoscopic activity grade (inactive/mild/moderate/severe) and correlations of parameters with disease location (L1/L2/L3 or E1/E2/E3) in CD and UC patients. Associations between endoscopic disease activity and laboratory parameters were assessed using Spearman's correlation. The true positive rate (sensitivity) was plotted as a function of the false positive rate (1-specificity) for various cut-off points to plot a receiver operating characteristic (ROC) curve. The area under the ROC curve (AUC) was used to measure the ability of parameters to predict endoscopic severity. Multiple linear regression analysis with stepwise deletion was performed based on FC, CDAI/CAI, CRP, ESR, and PCT in order to construct a combined score that best predicted the endoscopy activity.

## RESULTS

### Patients and their characteristics

In total, 136 consecutive IBD patients and 25 recruited IBS patients who met the inclusion and exclusion criteria were enrolled between August 2014 and January 2015.



**Figure 1** Median fecal calprotectin levels in Crohn's disease, ulcerative colitis, and irritable bowel syndrome patients, illustrated by box plots. The box indicates the lower and upper quartiles, and the horizontal line in the middle of the box is the median. The 95% confidence interval is indicated by the whiskers, and values outside the whiskers are individual outliers. FC: Fecal calprotectin; IBD: Inflammatory bowel disease; CD: Crohn's disease; UC: Ulcerative colitis; a,b: the sample numbers of fecal calprotectin extreme values in box plot.

During the study period, six patients (three CICD, two CD-related surgery, and one UC patients) underwent colonoscopy twice. Thus, a total of 142 endoscopies were performed in the 136 IBD patients. FC, CDAI/CAI, CRP and ESR were successfully measured in all included IBD patients. PCT was measured in 67 cases with CD, 18 cases with CD-related surgery, and 41 cases with UC. No adverse events happened when performing the ileo-colonoscopy. The demographic characteristics of the included patients are shown in Table 1.

Because the small bowel is not accessible in conventional colonoscopy, small-bowel CD patients are routinely determined to be endoscopically in remission according to SES-CD, but are shown to have active lesion by double-balloon or capsule endoscopy. We hypothesized that the evaluations could correlate more closely with the SES-CD in CICD patients. Later in this article we performed the endoscopy disease activity analysis mainly in three subgroup patients: CICD patients, CD-related surgery patients, and UC patients. Also, we included small bowel CD patients in the analysis of the correlation of non-invasive disease-activity parameters stratified according to disease location.

### Noninvasive parameters according to endoscopy-based inflammation categories

Baseline FC, clinical activity index (CDAI or CAI), and laboratory indexes (CRP, ESR, and PCT) according to endoscopy-based classification of active and inactive IBD patients and IBS patients are presented in Table 2. The median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 0-49.7) µg/g, respectively (Figure 1). IBS patients had significantly lower FC levels than the three subgroups of endoscopically active IBD patients ( $P < 0.001$ ). Indeed, IBS patients also had

significantly lower levels of FC when compared with the three subgroups of IBD patients without endoscopic inflammation ( $P < 0.05$ , Table 2). After the IBD patients were grouped into CICD, CD-related surgery, and UC subgroups, the median FC values were 695.0 (IQR, 147.1-1805.0), 188.5 (IQR, 72.06-559.7), and 497.9 (IQR, 131.7-1198.0) µg/g, respectively ( $P < 0.01$ ). Within each IBD subgroup, the evaluations were compared between the endoscopically active and inactive patients, and FC yielded a significant difference in the CICD and UC subgroups. But in the CD-related surgery patients, FC values showed no difference based on Rutgeerts score-classified endoscopic inflammation. Also as shown in Table 2, differences in CDAI/CAI, CRP, and ESR according to endoscopy-based inflammation status were observed in CICD patients and UC patients, but not in CD-related surgery patients. With regard to PCT, no significant difference was detected in the three groups of IBD patients.

Tables 3 and 4 summarize the median noninvasive parameter values for inactive, mild, moderate, and severe endoscopic grades in CICD and UC patients. In the two subgroups of patients, FC had the clinical usage to distinguish inactive from mild and moderate from severe endoscopic activity; however, FC failed to distinguish mild from moderate endoscopic activity. For clinical activity index, CDAI not only could distinguish inactive from mild endoscopic activity, but also moderate from severe endoscopic activity in CICD patients. For CAI, a significant difference could be detected between inactive vs mild and mild vs moderate endoscopic activity. CRP and ESR could only distinguish moderate from severe endoscopic activity in UC patients. Also, no Rutgeerts score-based endoscopic activity grade was individually distinguishable by noninvasive parameters. Median FC values according to endoscopic activity grade in three subgroups of IBD patients are vividly illustrated in Figure 2.

### Clinical activity and endoscopic activity


Base on CDAI/CAI, 34 CICD, 19 CD-related surgery, and 25 UC patients were in clinical remission (CDAI  $\leq 150$ /CAI  $\leq 4$ ). Among the three subgroups of IBD patients in clinical remission, 14/34, 7/19, and 13/25 patients showed active endoscopic inflammation, respectively (SESCD  $\geq 4$ /Rutgeerts  $\geq 2$ /Mayo  $\geq 3$ ). The noninvasive biomarker values in the three subgroups of IBD patients in clinical remission with and without evidence of endoscopic inflammation are shown in Supplementary Table 1. For CICD and UC patients in clinical remission, FC, CRP, and ESR differed significantly between the endoscopically active and inactive patients, being higher in the group with endoscopic active disease. However, no noninvasive biomarker in the 19 CD-related surgery patients in clinical remission differed significantly between active and inactive disease at ileo-colonoscopy.

The sensitivities and specificities of FC at a cut-

**Table 2** Descriptive statistics of noninvasive evaluations for endoscopy-based classification of inflammation for inflammatory bowel disease and irritable bowel syndrome patients

	CICD		CD-related surgery		UC		IBS <i>n</i> = 25
	Inactive, <i>n</i> = 21	Active, <i>n</i> = 35	Inactive, <i>n</i> = 15	Active, <i>n</i> = 10	Inactive, <i>n</i> = 12	Active, <i>n</i> = 33	
FC (μg/g)							
Median	131.72 <sup>1,3</sup>	1795.8 <sup>1,2</sup>	142.97 <sup>3</sup>	229.27 <sup>2</sup>	45.31 <sup>1,3</sup>	690.6 <sup>1,2</sup>	9.9 <sup>2,3</sup>
Range	(0-658.71)	(264.64-2266.07)	(0.02-1805.0)	(0-1805.0)	(6.7-189.42)	(74.93-2266.01)	(0-385.4)
CDAI/CAI							NA
Median	63.12 <sup>1</sup>	168.45 <sup>1</sup>	81	135.64	1 <sup>1</sup>	6 <sup>1</sup>	
Range	(32.2-155.0)	(46.8-364.0)	(37.8-192.8)	(38.8-327.1)	(0-4)	(1-17)	
CRP (mg/L)							NA
Median	0.48 <sup>1</sup>	20.57 <sup>1</sup>	2.1	4.37	0.39 <sup>1</sup>	4 <sup>1</sup>	
Range	(0.10-12.88)	(0.2-79.8)	(0.13-134.6)	(0.10-41.20)	(0.04-2.1)	(0.08-65.40)	
ESR (mm/h)							NA
Median	8.0 <sup>1</sup>	30.0 <sup>1</sup>	9	17	4.3 <sup>1</sup>	14 <sup>1</sup>	
Range	(1.0-57.0)	(5.0-123.0)	(1.0-92.0)	(2.0-41.0)	(2.0-15.0)	(2.0-100.0)	
PCT (ng/mL)							NA
Median	0.037	0.043	0.028	0.025	0.028	0.025	
Range	(0-4.39)	(0-5.02)	(0-0.082)	(0-0.058)	(0-0.082)	(0-0.058)	

<sup>1</sup>Identical letters indicate significant differences between the three inactive and active IBD patient groups (Mann-Whitney *U*-tests, *P* < 0.001 for all); <sup>2</sup>For all indices, IBS patients had significantly lower FC levels than the three groups of active IBD patients (Mann-Whitney *U*-tests, *P* < 0.001 for all); <sup>3</sup>IBS patients had significantly lower FC levels than the three groups of endoscopic remission IBD patients (Mann-Whitney *U*-tests, for CICD and CD-related surgery patients, *P* < 0.001; for UC patients, *P* < 0.05). CICD: Colonic or ileo-colonic Crohn's disease; CD: Crohn's disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome; FC: Fecal calprotectin; CDAI/CAI: Clinical activity index; PCT: Procalcitonin; NA: Not applicable.



**Figure 2** Median fecal calprotectin levels according to endoscopic activity grade in three subgroups of inflammatory bowel disease patients, illustrated by box plots. A: The median FC levels in CICD patients grouped by SES-CD. B: The median FC levels in CD-related surgery patients grouped by Rutgeerts score. C: The median FC levels in UC patients grouped by Mayo score. a: the sample numbers of fecal calprotectin extreme values in box plots; FC: Fecal calprotectin; CD: Crohn's disease; UC: Ulcerative colitis; CICD: Colonic or ileo-colonic Crohn's disease; SES-CD: Simple endoscopic score for Crohn's disease.

off value of 250 μg/g, CRP ≥ 5 mg/L, and ESR ≥ 10 mm/h in discriminating patients with active disease at ileo-colonoscopy in CICD and UC patients in clinical

remission are shown in Table 5. AUCs for FC to detect active endoscopic inflammation were 0.91 and 0.96, for the two subgroups of IBD patients in clinical

**Table 3** Noninvasive parameters according to endoscopic activity grade in colonic or ileo-colonic Crohn's disease patients

	Inactive, $n_1 = 21$	Mild activity, $n_2 = 8$	Moderate activity, $n_3 = 9$	Severe activity, $n_4 = 18$
FC, median (range)	125.7(0-658.7)	717.8 (137.7-1805.0)	1211.8 (660.8-1805.0)	1805.0 (264.6-2266.1)
<i>P</i> value		< 0.05	NS	< 0.05
CDAI, median (range)	63.1 (32.2-155.0)	125.4 (46.8-157.8)	145.1 (75.0-234.9)	201.4 (64.7-364.0)
<i>P</i> value		< 0.05	NS	< 0.05
CRP, median (range)	0.48(0.1-12.9)	5.1 (0.20-48.1)	15.0 (0.6-70.8)	30.6 (1.1-79.8)
<i>P</i> value		NS	NS	< 0.05
ESR, median (range)	8.0(1.0-57.0)	22.0 (5.0-68.0)	28.0 (8.9-95.0)	37.0 (5.5-123.0)
<i>P</i> value		NS	NS	< 0.05
PCT, median (range)	0.037 (0-4.39)	0.038 (0.021-0.064)	0.038 (0-0.137)	0.049 (0.02-5.02)
<i>P</i> value		NS	NS	NS

FC: Fecal calprotectin; CDAI: Clinical activity index; PCT: Procalcitonin; NS: No significant.

**Table 4** Noninvasive parameters according to endoscopic activity grade in ulcerative colitis patients

	Inactive, $n_1 = 12$	Mild activity, $n_2 = 12$	Moderate activity, $n_3 = 16$	Severe activity, $n_4 = 5$
FC, median (range)	45.3 (6.7-189.42)	474.8 (74.9-1805.0)	769.9 (186.8-2266.1)	1704.6 (788.4-2092.4)
<i>P</i> value		< 0.001	NS	< 0.05
CAI, median (range)	1 (0-4)	2.5 (1-8)	6.5 (2-17)	9 (8-15)
<i>P</i> value		< 0.05	< 0.001	NS
CRP, median (range)	0.39 (0.04-2.10)	1.9 (0.26-65.40)	4.7 (0.08-28.19)	16.4 (7.1-53.2)
<i>P</i> value		NS	NS	< 0.05
ESR, median (range)	4.3 (2.0-15.0)	8.5 (2.0-40.0)	14.0 (2.0-88.0)	45.0 (24.0-100.0)
<i>P</i> value		NS	NS	< 0.05
PCT, median (range)	0.03 (0-0.041)	0.031 (0.023-0.127)	0.044 (0.021-0.538)	0.035 (0.026-0.085)
<i>P</i> value		NS	NS	NS

FC: Fecal calprotectin; CAI: Clinical activity index; PCT: Procalcitonin; UC: Ulcerative colitis; NS: No significant.

**Table 5** Sensitivity, specificity, positive predictive value, and negative predictive value of fecal calprotectin, CRP, and ESR in predicting endoscopic active disease in inflammatory bowel disease patients in clinical remission

	FC $\geq 250$ $\mu\text{g/g}$	CRP $\geq 5$ mg/L	ESR $\geq 10$ mm/h
Colonic or ileum-colonic CD (%)			
Sensitivity	93	46.2	61.5
Specificity	70	83.3	66.7
PPV	68.4	75.0	53.3
NPV	93.3	73.1	73.7
AUC	0.91	0.76	0.71
<i>P</i> value	< 0.001	0.011	0.042
UC			
Sensitivity	84.6	23.1	46.2
Specificity	100	100	83.3
PPV	100	100	75.0
NPV	85.7	54.5	58.8
AUC	0.96	0.84	0.76
<i>P</i> value	< 0.001	0.004	0.028

CD: Crohn's disease; UC: Ulcerative colitis; FC: Fecal calprotectin; PPV: Positive predictive value; NPV: Negative predictive value; AUC: Area under the ROC curve.

remission, respectively, suggesting that FC is the most accurate biomarker to predict preclinical active inflammation. In CICD patients in clinical remission, FC at the cut-off value 250  $\mu\text{g/g}$  had the highest

sensitivity (93%) and a moderate specificity (70%) to predict active lesion, CRP had the highest specificity (83.3%) but lowest sensitivity (46.2%). ESR had a mild sensitivity and specificity of 61.5%, 66.7%, respectively. In UC patients in clinical remission, both FC and CRP had a 100% specificity to identify active disease, but the sensitivity of CRP was much lower (23.1%) compared with FC (84.6%). Also, all the noninvasive biomarkers were not useful as diagnostic tests for mucosal inflammation in CD-related surgery patients in clinical remission.

#### Correlation of noninvasive evaluations with endoscopic disease activity

Of 56 CICD patients, the SES-CD correlated significantly with levels of FC (Spearman's rank correlation coefficient,  $r = 0.802$ ), CDAI ( $r = 0.734$ ), CRP ( $r = 0.658$ ), and ESR ( $r = 0.557$ ) ( $P < 0.01$  for all). However, PCT failed to significantly correlate with the SES-CD ( $r = 0.209$ ,  $P = 0.19$ ). In the 25 CD-related surgery patients, the median time between surgery and the endoscopic examination at entry was 432 (IQR, 266-755) d. There was no significant correlation between endoscopic score and the time from surgery to the endoscopic examination ( $P = 0.76$ ). Noninvasive evaluations had no significant correlation with Rutgeerts score. In 45 UC patients, the Mayo score correlated closely with

**Table 6** Sensitivity, specificity, positive predictive value, and negative predictive value of FC, CDAI/CAI, CRP, ESR, and CAF in predicting endoscopic active disease in three groups of inflammatory bowel disease patients

	FC $\geq$ 250 $\mu$ g/g	CDAI > 150/CAI > 4	CRP $\geq$ 5 mg/L	ESR $\geq$ 10 mm/h	CFA $\geq$ 850 or $\geq$ 150
Colonic or ileum-colonic CD (%)					
Sensitivity	97.1	60	71.4	82.8	91.4
Specificity	71.4	95.2	90.5	57.1	90.5
PPV	85	95.5	92.6	76.3	94.1
NPV	93.8	58.8	65.5	66.7	86.4
Accuracy	87.5	73.2	78.6	73.2	91.1
CD-related surgery (%)					
Sensitivity	50.0	40.0	50.0	60.0	NA
Specificity	66.7	73.3	73.3	53.3	NA
PPV	50	50.0	55.6	46.2	NA
NPV	66.7	64.7	68.8	66.7	NA
Accuracy	60	60.0	64.0	56.0	NA
UC					
Sensitivity	87.9	60.6	42.4	63.6	92.8
Specificity	100	100	100	83.3	91.7
PPV	100	100	100	91.3	96.8
NPV	75.0	48.0	38.7	45.5	78.6
Accuracy	91.1	71.1	57.8	68.89	91.1

CD: Crohn's disease; UC: Ulcerative colitis; FC: Fecal calprotectin; CDAI/CAI: Clinical activity index; CFA: Clinical FC activity; PPV: Positive predictive value; NPV: Negative predictive value.

FC ( $r = 0.837$ ), followed by CAI ( $r = 0.776$ ), ESR ( $r = 0.644$ ), and CRP ( $r = 0.634$ ) ( $P < 0.001$  for all).

#### Correlations of noninvasive evaluations with disease location

Supplementary Table 2 describes the relationship between noninvasive evaluations and disease location in CD and UC patients. According to CD disease location, there were 22 (22.7%) cases with L1 (ileal) disease, 11 (11.3%) with L2 (colonic) disease, and 64 (66%) with L3 (ileo-colonic) disease. There was no significant difference between FC levels and disease location in CD patients ( $P = 0.361$ ). FC also did not differ between those with L2 or L3 disease vs those with L1 disease ( $P = 0.24$ ). In UC patients, extensive colitis UC (E3) was associated with significantly higher FC levels compared with distal colitis (E2;  $P = 0.001$ ) and left-sided colitis (E1;  $P < 0.001$ ) UC patients.

#### Specificity, sensitivity, and diagnostic accuracy

The performance data of FC, clinical activity index (CDAI or CAI), CRP, ESR, and CAF in predicting the presence of endoscopic activity in the three categories of IBD patients are listed in Table 6. In CICD patients, the ROC curves revealed that the AUCs were 0.93 and 0.85 for FC and CDAI, respectively, for the detection of endoscopic active disease, followed by elevated CRP (AUC = 0.81) and ESR (AUC = 0.77), as shown in Supplementary Figure 1A. We tested a FC threshold of 250  $\mu$ g/g, determined by our previous meta-analysis, to indicate endoscopic remission, with a 97.1% sensitivity and 71.4% specificity (PPV: 85.0%; NPV: 93.8%). As a non-invasive biomarker, FC had

the highest sensitivity, while CDAI had the highest specificity. We also constructed a Spearman's correlation based on the sums of differently emphasized FC, CDAI, CRP, ESR, and PCT. The scores based on the FC and CDAI proved consequently to be superior to other combinations of parameters or FC alone. The highest Spearman's correlation, 0.839, was obtained when using the following score:  $0.8 \times \text{FC} + 4.6 \times \text{CDAI}$ . The sensitivity for this score was 91.4% and the specificity was 90.5%, when using its resulting sum 850 as a cut-off value for endoscopic remission. The coefficients of multiple linear regression models to construct CFA are showed in Supplementary Table 3.

In UC, FC at a cutoff value of 250  $\mu$ g/g yielded a sensitivity, specificity, PPV, and NPV of 87.9%, 100%, 100%, and 75%, respectively. The ROC curves revealed that the AUCs were 0.96 for FC, 0.88 for CAI, 0.86 for CRP, and 0.81 for ESR, as shown in Supplementary Figure 1B. FC and CAI both had a 100% specificity to predict active mucosal lesion, but CAI had much lower sensitivity. For UC patients, we also constructed the score:  $0.2 \times \text{FC} + 50 \times \text{CAI}$  (Spearman's correlation  $r = 0.868$ ). With a cut-off value of 150, the sensitivity for this score was 92.8% and the specificity was 91.7%. Supplementary Table 3 describes the coefficients of multiple linear regression models to construct CFA.

However, FC, CDAI, CRP, ESR, and PCT were not useful as diagnostic tests for mucosal inflammation in CD-related surgery patients, with AUCs of 0.58 ( $P = 0.52$ ), 0.69 ( $P = 0.11$ ), 0.53 ( $P = 0.82$ ), 0.51 ( $P = 0.93$ ), and 0.49 ( $P = 1.00$ ), respectively. Table 6 shows the sensitivities and specificities of FC, CDAI, CRP, and ESR for the prediction of endoscopic recurrence.

## DISCUSSION

In this study, we found that FC was a more useful noninvasive marker of intestinal inflammation compared with the other evaluations in CICD and UC patients. However, FC did not discriminate between endoscopic recurrent and remission in CD-related surgery patients, based on the Rutgeerts score. Our data confirmed the findings that IBD could be differentiated from IBS using FC. We also found that both FC and clinical activity index had a good correlation with SES-CD and Mayo score, and a combined score (CFA) of FC with the clinical activity index had better diagnostic accuracy to detect endoscopic active disease. In addition, we demonstrated that considerable IBD patients in clinical remission actually had active endoscopic inflammation, and FC had better diagnostic accuracy in detecting preclinical mucosal inflammation in CICD and UC patients.

Why the FC was better than the others? Active lesion in IBD was associated with an acute inflammatory reaction and migration of leukocytes to the gut, resulting in considerable protective factors released to blood and stool<sup>[22]</sup>. For CRP in serum, its short half-life made it a valuable biomarker to detect disease activity in IBD, but the low sensitivity to detect active inflammation, especially in UC patients, limited its clinical usage<sup>[23]</sup>. ESR would take several days to respond or decrease when inflammation status was changed, so the ESR also appeared to be a less accurate measure to disease activity in IBD compared with CRP<sup>[22]</sup>. In this study, our results that elevated CRP and ESR had moderate efficiency to detect active endoscopic inflammation in IBD patients are consistent with previous studies. For PCT, to date only two studies, with small sample size, evaluated the correlation between PCT and endoscopic activity score, and controversial results were achieved<sup>[24,25]</sup>. We tested the PCT level and no significant difference was detected in patients with active endoscopic disease in comparison with the three subgroups of IBD patients with inactive disease. This result suggested that PCT is a more specific marker of bacterial infection, however, active IBD mainly involves the disorder of the immune system and defensive deficiency of the mucosa. FC is a surrogate marker of neutrophil turnover in the digestive tract and might become a better biomarker in measuring bowel inflammation for researchers and clinicians<sup>[26]</sup>. Unlike "traditional" serological biological markers, FC had higher specificity for the assessment of gastrointestinal inflammatory conditions. Indeed, IBS patients still had significantly lower levels of FC when compared with IBD patients in endoscopic remission. A high level of FC could be a reliable marker of persistent active microscopic inflammation. FC also had the advantage of showing excellent stability in feces at room temperature, for up to 3 d<sup>[27]</sup>. Those characteristics allowed patients themselves to retrieve samples in their homes and mail them to a hospital

where they were frozen, allowing for batching of samples.

In Western countries, it was reported that FC was a reliable marker of endoscopic activity in both CD and UC. Several prospective population-based studies showed that disease location and disease behavior differed between Western and Asian countries, especially for CD<sup>[3-5,28]</sup>. As CD is characterized by patchy and segmental inflammation, it is not reasonable to use SES-CD to quantify disease activity in small bowel CD and CD-related surgery patients. Schoepfer *et al.*<sup>[17]</sup>, Bjorksten *et al.*<sup>[29]</sup>, Sipponen *et al.*<sup>[30]</sup>, and Vieira *et al.*<sup>[31]</sup> used SES-CD or CDEIS to quantify CD-related surgery patients and ileal CD patients. All of these studies also demonstrated that FC showed a correlation with disease location, but using the SES-CD to quantify disease activity in isolated ileum disease was inappropriate because the small bowel was not accessible to routine endoscopic techniques. Sipponen *et al.* then made an improvement<sup>[32]</sup>: they used the terminal ileal SES-CD to assess the small bowel CD activity. As the terminal ileum was only the window of the small intestine, they failed to correlate FC with terminal ileal SES-CD. Thus, in this study, we assessed only CICD disease activity using the SES-CD score. Similarly, in the current study, we found that when combining the CICD patients with the small bowel CD patients, FC appeared to be a more sensitive biomarker in CICD, with the correlation coefficient increased from 0.692 to 0.802. The cut-off point of FC at 250  $\mu\text{g/g}$  was confirmed in our study by ROC curve analysis with a sensitivity of 97.1%, specificity of 71.4%, and accuracy of 87.5%. In clinical scenario, clinicians should note that 28.6% of endoscopic remission patients would be identified as false positives and receive excessive treatment. Meanwhile, treatment will be delayed in 2.9% of patients with active disease.

On the other hand, previous studies demonstrated that the correlation coefficients between endoscopic activity in UC patients and FC levels ranged from 0.49 to 0.83<sup>[31,33-35]</sup>, probably due to the different endoscopic scores used in those studies. In our study, the Mayo score correlated closely with FC ( $r = 0.837$ ). The accuracy rates of FC  $\geq 250 \mu\text{g/g}$  and CAI  $> 4$  to detect endoscopic inflammation were 91.1% and 71.1%, respectively. Because the CAI scores underestimated endoscopic activity and depended almost exclusively on clinical features that were often subjective and non-specific, FC was a more promising marker of endoscopic inflammation in UC patients.

The introduction of immunosuppressive and biological therapies has led to a decline in the rate of IBD-related surgery<sup>[36-38]</sup>. However, the postoperative relapse rates have been reported to be rather high. Accurate monitoring of disease activity is necessary in postoperative IBD patients. Scarpa *et al.*<sup>[36]</sup>, Lamb *et al.*<sup>[37]</sup>, and Lasson *et al.*<sup>[38]</sup> failed to show a correlation between the FC and CD. However, Yamamoto *et al.*<sup>[39]</sup> and Sorrentino *et al.*<sup>[40]</sup> suggested that FC was

a promising marker in postoperative CD patients. Our results suggested that it was not appropriate to predict endoscopic activity using FC in CD-related surgery patients. These varying results might be explained by the different time intervals from the surgical resection and performance of different types of resection. For IBD-related surgery patients, surgeons would resect the severe macroscopic disease and retain the normal function bowel as much as possible. Therefore, considerable patients had no macroscopic anastomotic recurrence, but actually had microscopic inflammation, which would increase the FC concentration. Also, for patients with small bowel resection, the recurrence of disease would more likely involve proximal small bowel instead of anastomosis. Those conditions would result in higher FC level but lower endoscopic activity grade. Thus, we failed to correlate the FC with Rutgeerts score, but those patients with high FC level would easily experience worse prognosis.

Although clinical activity index was subjective in our study, we found that CDAI/CAI had moderate correlation with endoscopy score, which challenged previous observations of poor correlation between clinical activity index and endoscopic score. This might be explained by the fact that we separated the small bowel CD and CD-related surgery patients from CIBD patients. For assessing endoscopic activity, FC had the highest sensitivity, while CDAI had the highest specificity in CIBD patients. Meanwhile, FC and CAI both had a 100% specificity to predict active mucosal lesion in UC patients, but CAI had much lower sensitivity. Clearly, no one parameter clearly outperformed the other. Thus, it is of interest to consider a comprehensive index which may allow clinicians to more reliably assess the ileo-colonoscopy inflammation. We developed a combined score (CFA) based on FC and CDAI/CAI in CIBD and UC patients. The sensitivity for CFA was 91.4% and the specificity was 90.5%, when using its resulting sum 850 as a cut-off value for endoscopic remission in CIBD patients. With a cut-off value of 150, the sensitivity for this score was 92.8% and the specificity was 91.7% in UC patients. In both groups, CFA had higher accuracy to identify endoscopic active disease than the FC and CDAI/CAI separately. Clinicians could identify endoscopic active disease more accurately with CFA through a short inquiry and a FC test.

Emerging data show that remission of symptoms in IBD patients may not indicate remission of mucosal inflammation at endoscopy<sup>[41,42]</sup>. In our cohort, in the three subgroups of IBD patients in clinical remission, 41% of CIBD patients, 36.8% of CD-related surgery patients, and 52% of UC patients had active endoscopic inflammation. The sensitivities of CDAI > 150 and CAI > 4 were 60.0% and 60.6%, respectively, to detect active endoscopic inflammation. Thus, the clinical activity index underestimated the endoscopic inflammation. However, current ECCO guidelines

emphasize that routine endoscopy for IBD patients in clinical remission is unnecessary, unless it is likely to change patient management<sup>[12]</sup>. In this setting, defining IBD disease activity using FC might discriminate between those who have preclinical relapse and those with quiescent IBD, or to protect those who dissimulate against themselves. One previous study investigated FC as a marker of inflammation in 48 IBD patients in clinical remission<sup>[43]</sup>. FC levels above a cut-off of 30  $\mu\text{g/g}$  indicated endoscopic inflammation with a 93.7% sensitivity and 50% specificity. We separately analyzed the CD and UC patients with an acknowledged cut-off value of 250  $\mu\text{g/g}$ , and found that FC was higher in patients with active disease (93% sensitivity/70% specificity for SES-CD  $\geq 4$  and 86.4% sensitivity/100% specificity for Mayo score  $\geq 3$ ), confirming the value of FC in IBD patients in clinical remission. As a screening tool in IBD patients in clinical remission, FC could be measured frequently to detect preclinical mucosal inflammation and guide clinicians timely change their clinical regimen.

Our study had several limitations. First, to more accurately reflect the efficacy of FC, we categorized IBD patients into three subgroups, resulting in a relatively small number of patients in each subgroup. Second, because of the design of the study, we did not analyze small bowel CD patients' mucosal inflammation activity; thus, our results could not be extrapolated to small bowel CD patients. Also, the number of patients with purely ileal disease and colonic CD was limited, and we failed to detect a difference in FC levels according to disease location in CD patients, which thus needs to be further explored. Finally, the cut-off values for FC needs to be further explored. The difference between manufacture assays, heterogeneous operating conditions, no consensus definitions of endoscopic remission, and different patient spectrum could be accounted for when trying to define the optimal cut point. The optimal cut point may be different depending on if you are using this as a triage tool or as the final assessment for active disease. Thus, it may not be possible to set "an optimal cut point" for all scenarios and clinicians should form their own optimal cut-off value when implementing FC in clinical activity.

In conclusion, FC is the most promising noninvasive marker than the others for assessing mucosal inflammation in CIBD and UC patients, but not in CD-related surgery patients. Furthermore, CFA calculated as  $0.8 \times \text{FC} + 4.6 \times \text{CDAI}$  for colonic (ileo-colonic) CD or  $0.2 \times \text{FC} + 50 \times \text{CAI}$  for UC patients might be more accurate for IBD activity evaluation. FC also has the ability to detect active residual mucosal inflammation in IBD patients in clinical remission to guide clinicians to timely change their clinical regimen. With the increasing recognition of the clinical value of biomarkers, the next step is implementation of marker-guided treatment in patients with IBD. To achieve this, we should attempt to

improve the standardization of pre-analytical procedures and further clinical trials are warranted to demonstrate its value in clinical practice.

## ARTICLE HIGHLIGHTS

### Research background

Inflammatory bowel disease (IBD) is characterized by periods of relapsing-remitting. At present, most clinicians monitor IBD activity and guide therapeutic decisions based on clinical activity indexes. However, emerging data show that clinical assessment indexes correlate poorly with endoscopic activity and IBD patients with clinically quiescent disease may still have residual mucosal inflammation. An endoscopic procedure is considered the gold standard for assessing disease activity. However, the endoscopy is invasive, uncomfortable, and expensive.

### Research motivation

A simple, acceptable, and specific evaluation is needed to play an adjunctive role in the assessment of IBD activity. The specific and noninvasive evaluation could instruct clinicians to timely choose reasonable therapy regimen and predict prognosis. Furthermore, a new evaluation that can detect increased disease activity earlier before any clinical symptoms have occurred could change disease course, enabling the most cost-effective use of medical resources.

### Research objectives

The main objective of this study was to assess the efficacy of noninvasive evaluations for the disease activity in colonic or ileo-colonic Crohn's disease (CICD), CD-related surgery, and ulcerative colitis (UC) patients and further to optimize the accuracy of those noninvasive evaluations in detecting active residual mucosal inflammation in IBD patients in clinical remission. In our study we confirmed the efficacy of fecal calprotectin (FC) and the new clinical FC activity (CFA) in assessing disease activity in CICD and UC patients. In future, clinicians and researchers could use FC to recognize an imminent endoscopic flare. What's more, FC could be measured frequently as a clinical activity index to detect preclinical mucosal inflammation in clinical remission patients.

### Research methods

In total, 136 consecutive IBD patients and 25 recruited IBS patients were enrolled. For all IBD patients, the day before the endoscopy, fecal and blood samples were collected to measure FC, CRP, ESR, and PCT. At the same time, the patients were asked to complete a case report to calculate their clinical activity index (CDAI/CAI). Then, endoscopic activity was determined for CICD patients with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and UC patients with the Mayo score. The efficacies of these evaluations to predict the endoscopic activity were assessed by Mann-Whitney test,  $\chi^2$  test, Spearman's correlation, and multiple linear regression analysis. In our study, multiple linear regression analysis with stepwise deletion was performed based on FC, CDAI/CAI, CRP, ESR, and PCT to construct a combined score, clinical FC activity (CFA), which could best predict the endoscopic activity. In clinical scenario, clinicians could identify endoscopic active disease more accurately with CFA through a short inquiry and a FC test.

### Research results

We found that FC and clinical FC activity (CFA) are useful, non-invasive, and sensitive stool markers for gut inflammation in both CICD and UC patients. However, the standard collection of fecal sample and best cutoff to predict endoscopic activity are needed to be solved.

### Research conclusions

This was the first study performed in China for disease activity analysis in the three groups of IBD patients separately. We also constructed a clinical FC activity (CFA) index to more accurately assess disease activity. Moreover, we found that FC had ability to detect active residual mucosal inflammation in IBD patients in clinical remission. Indeed, we also found that IBD patients in endoscopic remission still had significantly higher levels of FC when compared

with IBS patients. A high level of FC could be a reliable marker of persistent active microscopic inflammation. Then FC remission may indicate deep remission at histopathology level, which was proven to be a strong predictor of favorable prognosis in IBD. In future, the next step is to use FC to guide the clinicians to adjust the treatment regimen. We can schedule regular FC measurement and compare the change from baseline level to reflect the degree of response to treatment.

### Research perspectives

In our study, we confirmed the efficacy of FC in assessing disease activity in IBD patients. In future, we recommend periodic FC measurements instead of a single measurement in monitoring disease activity and deciding the treatment regimen. The clinical remission and biomarker healing could be the new therapeutic goals in IBD patients. To achieve those goals, multicenter, large-sample, randomized clinical trials are warranted to prove their value in clinical practice.

## REFERENCES

- 1 **Xavier RJ**, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; **448**: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
- 2 **Ananthakrishnan AN**, Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, Issa M, Otterson MF, Binion DG. Permanent work disability in Crohn's disease. *Am J Gastroenterol* 2008; **103**: 154-161 [PMID: 18076736 DOI: 10.1111/j.1572-0241.2007.01561.x]
- 3 **Ng SC**, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, Li MF, Ng KK, Kamm MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MN, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisesongsa P, Manatsathit S, Rerknimitr R, Aniwang S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJ, Chan FK; Asia-Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. *Gastroenterology* 2013; **145**: 158-165.e2 [PMID: 23583432 DOI: 10.1053/j.gastro.2013.04.007]
- 4 **Zhao J**, Ng SC, Lei Y, Yi F, Li J, Yu L, Zou K, Dan Z, Dai M, Ding Y, Song M, Mei Q, Fang X, Liu H, Shi Z, Zhou R, Xia M, Wu Q, Xiong Z, Zhu W, Deng L, Kamm MA, Xia B. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of "western" disease. *Inflamm Bowel Dis* 2013; **19**: 1839-1845 [PMID: 23669403 DOI: 10.1097/MIB.0b013e31828a6551]
- 5 **Zeng Z**, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, Peng L, Chen J, Yin Q, Zhao C, Zhou H, Yuan S, Hao Y, Qian J, Ng SC, Chen M, Hu P. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. *J Gastroenterol Hepatol* 2013; **28**: 1148-1153 [PMID: 23432198 DOI: 10.1111/jgh.12164]
- 6 **Schoepfer AM**, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. *J Crohns Colitis* 2012; **6**: 412-418 [PMID: 22398068 DOI: 10.1016/j.crohns.2011.09.008]
- 7 **Baars JE**, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. *Inflamm Bowel Dis* 2012; **18**: 1634-1640 [PMID: 22069022 DOI: 10.1002/ibd.21925]
- 8 **Berrill JW**, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. *Aliment Pharmacol Ther* 2013; **38**: 44-51 [PMID: 23668698 DOI: 10.1111/apt.12335]
- 9 **af Björkstén CG**, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term

- endoscopic remission in anti-TNF-treated luminal Crohn's disease. *Scand J Gastroenterol* 2013; **48**: 543-551 [PMID: 23477356 DOI: 10.3109/00365521.2013.772230]
- 10 **Frøslie KF**, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007; **133**: 412-422 [PMID: 17681162 DOI: 10.1053/j.gastro.2007.05.051]
  - 11 **Meucci G**, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D'Inca R, Terpin M, Lombardi G; IG-IBD. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. *Inflamm Bowel Dis* 2012; **18**: 1006-1010 [PMID: 21830282 DOI: 10.1002/ibd.21838]
  - 12 **Annese V**, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kiebllich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]
  - 13 **van Deen WK**, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. *Inflamm Bowel Dis* 2014; **20**: 1747-1753 [PMID: 25137415 DOI: 10.1097/MIB.000000000000139]
  - 14 **Gauss A**, Geib T, Hinz U, Schaefer R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. *Medicine (Baltimore)* 2016; **95**: e3477 [PMID: 27100452 DOI: 10.1097/MD.0000000000003477]
  - 15 **Bodelier AG**, Jonkers D, van den Heuvel T, de Boer E, Hameeteman W, Masclee AA, Pierik MJ. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. *Dig Dis Sci* 2017; **62**: 465-472 [PMID: 27933473 DOI: 10.1007/s10620-016-4397-6]
  - 16 **Daperno M**, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. *Gastrointest Endosc* 2004; **60**: 505-512 [PMID: 15472670 DOI: 10.1016/S0016-5107(04)01878-4]
  - 17 **Schoepfer AM**, Beglinger C, Straumann A, Trummel M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. *Am J Gastroenterol* 2010; **105**: 162-169 [PMID: 19755969 DOI: 10.1038/ajg.2009.545]
  - 18 **Rutgeerts P**, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterology* 1990; **99**: 956-963 [PMID: 2394349 DOI: 10.1016/0016-5085(90)90613-6]
  - 19 **Schroeder KW**, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987; **317**: 1625-1629 [PMID: 3317057 DOI: 10.1056/NEJM198712243172603]
  - 20 **Best WR**, Beckett JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701]
  - 21 **Rachmilewitz D**. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. *BMJ* 1989; **298**: 82-86 [PMID: 2563951 DOI: 10.1136/bmj.298.6666.82]
  - 22 **Vermeire S**, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut* 2006; **55**: 426-431 [PMID: 16474109 DOI: 10.1136/gut.2005.069476]
  - 23 **Saverymuttu SH**, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. *Gut* 1986; **27**: 809-813 [PMID: 3732890 DOI: 10.1136/gut.27.7.809]
  - 24 **Oussalah A**, Laurent V, Bruot O, Guéant JL, Régent D, Bigard MA, Peyrin-Biroulet L. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease. *Aliment Pharmacol Ther* 2010; **32**: 1135-1144 [PMID: 21039675 DOI: 10.1111/j.1365-2036.2010.04459.x]
  - 25 **Koido S**, Ohkusa T, Takakura K, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H. Clinical significance of serum procalcitonin in patients with ulcerative colitis. *World J Gastroenterol* 2013; **19**: 8335-8341 [PMID: 24363525 DOI: 10.3748/wjg.v19.i45.8335]
  - 26 **Summerton CB**, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. *Eur J Gastroenterol Hepatol* 2002; **14**: 841-845 [PMID: 12172403 DOI: 10.1097/00042737-200208000-00005]
  - 27 **Burri E**, Beglinger C. IBD: Faecal calprotectin testing--the need for better standardization. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 583-584 [PMID: 25201042 DOI: 10.1038/nrgastro.2014.154]
  - 28 **Vester-Andersen MK**, Prosborg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, Munkholm P, Bendtsen F, Vind I. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. *Am J Gastroenterol* 2014; **109**: 705-714 [PMID: 24642581 DOI: 10.1038/ajg.2014.45]
  - 29 **af Björkstén CG**, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. *Scand J Gastroenterol* 2012; **47**: 528-537 [PMID: 22356594 DOI: 10.3109/00365521.2012.660542]
  - 30 **Sipponen T**, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. *Inflamm Bowel Dis* 2008; **14**: 40-46 [PMID: 18022866 DOI: 10.1002/ibd.20312]
  - 31 **Vieira A**, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. *BMC Res Notes* 2009; **2**: 221 [PMID: 19874614 DOI: 10.1186/1756-0500-2-221]
  - 32 **Sipponen T**, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. *Aliment Pharmacol Ther* 2008; **28**: 1221-1229 [PMID: 18752630 DOI: 10.1111/j.1365-2036.2008.03835.x]
  - 33 **Schoepfer AM**, Beglinger C, Straumann A, Trummel M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. *Inflamm Bowel Dis* 2009; **15**: 1851-1858 [PMID: 19462421 DOI: 10.1002/ibd.20986]
  - 34 **Schoepfer AM**, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummel M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. *Inflamm Bowel Dis* 2013; **19**: 332-341 [PMID: 23328771 DOI: 10.1097/MIB.0b013e3182810066]
  - 35 **Önal İK**, Beyazit Y, Şener B, Savuk B, Özer Etik D, Sayilir A, Öztaş E, Torun S, Özderin Özın Y, Tunç Demirel B, Ülker A, Dağlı Ü. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. *Turk J Gastroenterol* 2012; **23**: 509-514 [PMID: 23161295 DOI: 10.4318/tjg.2012.0421]
  - 36 **Scarpa M**, D'Inca R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturmiolo GC, D'Amico DF, Angriman I. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. *Dis Colon Rectum* 2007; **50**: 861-869 [PMID: 17473939 DOI: 10.1007/s10350-007-0225-6]

- 37 **Lamb CA**, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, Mansfield JC. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. *Br J Surg* 2009; **96**: 663-674 [PMID: 19384912 DOI: 10.1002/bjs.6593]
- 38 **Lasson A**, Strid H, Ohman L, Isaksson S, Olsson M, Rydström B, Ung KA, Stotzer PO. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy. *J Crohns Colitis* 2014; **8**: 789-795 [PMID: 24418661 DOI: 10.1016/j.crohns.2013.12.015]
- 39 **Yamamoto T**, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study. *United European Gastroenterol J* 2013; **1**: 368-374 [PMID: 24917985 DOI: 10.1177/2050640613501818]
- 40 **Sorrentino D**, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. *Clin Gastroenterol Hepatol* 2010; **8**: 591-599.e1; quiz e78-79 [PMID: 20139033 DOI: 10.1016/j.cgh.2010.01.016]
- 41 **Ferreiro-Iglesias R**, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. *J Clin Gastroenterol* 2016; Epub ahead of print [PMID: 27984399 DOI: 10.1097/MCG.0000000000000774]
- 42 **Assa A**, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R. Anti-TNF $\alpha$  Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. *Inflamm Bowel Dis* 2017; **23**: 791-797 [PMID: 28426458 DOI: 10.1097/MIB.0000000000001050]
- 43 **Voiosu T**, Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. *J Gastrointestin Liver Dis* 2014; **23**: 273-278 [PMID: 25267955]

**P- Reviewer:** Jadallah KA, Manguso F, Sergi CM **S- Editor:** Gong ZM **L- Editor:** Wang TQ **E- Editor:** Ma YJ





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045